^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

maplirpacept (TTI-622)

i
Other names: TTI-622, PF-07901801, TTI622, TTI 622, SIRPa-IgG4-Fc, PF 07901801, PF07901801
Associations
Company:
Pfizer
Drug class:
CD47 inhibitor
Associations
5d
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China (clinicaltrials.gov)
P1, N=10, Completed, Pfizer | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Nov 2024
Trial completion • Trial completion date • Metastases
|
maplirpacept (TTI-622)
5d
Phase classification • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)
18d
Trial completion
|
maplirpacept (TTI-622)
24d
Phase classification • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)
1m
Trial primary completion date
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
2ms
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Pfizer | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
Trial completion date • Trial primary completion date
|
maplirpacept (TTI-622)
2ms
Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
|
ALK positive • BCL6 rearrangement • BCL2 rearrangement
|
Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
3ms
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P1/2, N=4, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=70 --> 4 | Trial completion date: Feb 2029 --> May 2025 | Trial primary completion date: Feb 2027 --> May 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
3ms
TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
P1, N=189, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.
Trial termination • Combination therapy • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
3ms
Enrollment closed • Metastases
|
maplirpacept (TTI-622)
3ms
MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=90, Recruiting, Pfizer | Trial completion date: Mar 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Dec 2025
Trial completion date • Trial primary completion date • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
3ms
Trial completion date • Trial primary completion date • Combination therapy
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
3ms
Phase classification
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
5ms
Trial primary completion date • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
6ms
Trial completion date • Trial primary completion date • Combination therapy
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
7ms
Trial primary completion date • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
8ms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
P1/2, N=10, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
Trial termination • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)
8ms
Phase classification • Combination therapy
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
8ms
Enrollment change • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
9ms
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=13 --> 7
Enrollment closed • Enrollment change
|
maplirpacept (TTI-622)
10ms
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=32 --> 7
Enrollment closed • Enrollment change • Combination therapy
|
Darzalex Faspro (daratumumab and hyaluronidase-fihj) • maplirpacept (TTI-622)
11ms
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China (clinicaltrials.gov)
P1, N=9, Recruiting, Pfizer | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Aug 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Metastases
|
maplirpacept (TTI-622)
11ms
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
11ms
Phase classification • Combination therapy
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
11ms
Phase classification
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
12ms
A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma (ASH 2023)
Background Maplirpacept (PF-07901801) is an anti-CD47 fusion protein constructed to enhance phagocytosis and antitumor activity via inhibition of CD47-mediated signaling. All patients should have adequate bone marrow, hepatic, and renal function (eGFR ≥45 mL/min) and ECOG performance status ≤2. Exclusion criteria include prior treatment with an anti-CD47 agent, prior anti-CD20xCD3 containing regimen, refractoriness to an obinutuzumab monotherapy containing regimen, prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment, high grade B-cell lymphoma with BCL2 and Myc rearrangement, active bacterial, viral, fungal, mycobacterial, parasitic, or other infection.
Clinical • P1/2 data • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2)
|
MYC rearrangement • BCL2 rearrangement
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
12ms
A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ASH 2023)
Participants must provide a baseline tumor tissue sample (fresh or archival), for biomarker analysis. Exclusion criteria include previous treatment with anti-CD47, anti-CD19 (other than CAR-T) or immunomodulatory agents, prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment, and participants with active, uncontrolled viral, bacterial or fungal infections.
Clinical • P1/2 data • Combination therapy • IO biomarker
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
1year
Phase classification • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
1year
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
P1/2, N=10, Active, not recruiting, Pfizer | N=50 --> 10 | Trial completion date: Dec 2025 --> Feb 2024 | Trial primary completion date: Dec 2024 --> Feb 2024
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)
1year
Trial completion date • Trial primary completion date • Combination therapy
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
1year
The CD47-Blocking Immune Checkpoint Inhibitor Maplirpacept Does Not Interfere with Blood Transfusion Compatibility Testing (ASH 2023)
CD47 expression on RBCs was shown to interfere with pre-transfusion laboratory testing in patients treated with the anti-CD47 mAb, Hu5F9-G4 (Velliquette et al. Here we demonstrate that interference with blood compatibility testing is dependent upon the type of CD47-blocking agent. Decoy receptors such as Maplirpacept, unlike anti-CD47 mAb, do not interfere with blood group serologic testing, which may confer a significant clinical advantage by negating the need for additional approaches to prevent interference.
Checkpoint inhibition • IO biomarker
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD47 expression
|
magrolimab (ONO-7913) • maplirpacept (TTI-622)
1year
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P1b/2, N=70, Recruiting, Pfizer | Trial completion date: Jul 2026 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Mar 2027
Trial completion date • Trial primary completion date
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
1year
TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
P1a/1b, N=177, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=476 --> 177 | Trial completion date: Oct 2025 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
over1year
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
over1year
Enrollment open • Metastases
|
maplirpacept (TTI-622)
over1year
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
over1year
Enrollment change • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
over1year
New P1 trial • Metastases
|
maplirpacept (TTI-622)
over1year
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
over1year
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
P1, N=32, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
Trial completion date • Trial primary completion date • Combination therapy
|
Darzalex Faspro (daratumumab and hyaluronidase-fihj) • maplirpacept (TTI-622)
over1year
MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
P1b, N=56, Recruiting, Pfizer | N=14 --> 56 | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Nov 2024 --> Aug 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
over1year
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
P1/2, N=50, Recruiting, Pfizer | Phase classification: P2 --> P1/2 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
Phase classification • Trial completion date • Trial primary completion date • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)